Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.

Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, Hoyoux C, Chopinet C, Clapuyt P, Hammer F, Vikkula M, Boon LM.

Orphanet J Rare Dis. 2018 Oct 29;13(1):191. doi: 10.1186/s13023-018-0934-z.

2.

Angiosarcoma arising from congenital primary lymphedema.

Janssens P, Dekeuleneer V, Van Damme A, Brouillard P, Revencu N, Clapuyt P, Ferreira I, Ballieux F, Vikkula M, Marot L, Baeck M, Boon LM.

Pediatr Dermatol. 2018 Nov;35(6):e382-e388. doi: 10.1111/pde.13664. Epub 2018 Sep 14.

PMID:
30216524
3.

Multiple Cutaneous and Mucosal Venous Malformations.

Boon LM, Vikkula M.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2008 Sep 18 [updated 2018 May 17].

4.

Etiology and Genetics of Congenital Vascular Lesions.

Queisser A, Boon LM, Vikkula M.

Otolaryngol Clin North Am. 2018 Feb;51(1):41-53. doi: 10.1016/j.otc.2017.09.006. Review.

PMID:
29217067
5.

Venous Malformations of the Head and Neck.

Seront E, Vikkula M, Boon LM.

Otolaryngol Clin North Am. 2018 Feb;51(1):173-184. doi: 10.1016/j.otc.2017.09.003. Review.

PMID:
29217061
6.

Development of an international core outcome set for peripheral vascular malformations: the OVAMA project.

Horbach SER, van der Horst CMAM, Blei F, van der Vleuten CJM, Frieden IJ, Richter GT, Tan ST, Muir T, Penington AJ, Boon LM, Spuls PI; OVAMA Consensus Group.

Br J Dermatol. 2018 Feb;178(2):473-481. doi: 10.1111/bjd.16029. Epub 2018 Jan 19.

PMID:
28986976
7.

Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.

Nguyen HL, Boon LM, Vikkula M.

Semin Intervent Radiol. 2017 Sep;34(3):233-238. doi: 10.1055/s-0037-1604296. Epub 2017 Sep 11. Review.

8.

Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling.

Amyere M, Revencu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour JP, Martorell L, Mazereeuw-Hautier J, Pyeritz RE, Amor DJ, Bisdorff A, Blei F, Bombei H, Dompmartin A, Brooks D, Dupont J, González-Enseñat MA, Frieden I, Gérard M, Kvarnung M, Hanson-Kahn AK, Hudgins L, Léauté-Labrèze C, McCuaig C, Metry D, Parent P, Paul C, Petit F, Phan A, Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M.

Circulation. 2017 Sep 12;136(11):1037-1048. doi: 10.1161/CIRCULATIONAHA.116.026886. Epub 2017 Jul 7.

PMID:
28687708
9.

[Management of vascular anomalies in children].

Elajmi A, Clapuyt P, Hammer F, Bataille AC, Lengele B, Boon LM.

Ann Chir Plast Esthet. 2016 Oct;61(5):480-497. doi: 10.1016/j.anplas.2016.06.015. Epub 2016 Sep 15. French.

PMID:
27641115
10.

Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.

Baselga E, Roe E, Coulie J, Muñoz FZ, Boon LM, McCuaig C, Hernandez-Martín A, Gich I, Puig L.

JAMA Dermatol. 2016 Nov 1;152(11):1239-1243. doi: 10.1001/jamadermatol.2016.2905.

PMID:
27540637
11.

Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations.

Soblet J, Kangas J, Nätynki M, Mendola A, Helaers R, Uebelhoer M, Kaakinen M, Cordisco M, Dompmartin A, Enjolras O, Holden S, Irvine AD, Kangesu L, Léauté-Labrèze C, Lanoel A, Lokmic Z, Maas S, McAleer MA, Penington A, Rieu P, Syed S, van der Vleuten C, Watson R, Fishman SJ, Mulliken JB, Eklund L, Limaye N, Boon LM, Vikkula M.

J Invest Dermatol. 2017 Jan;137(1):207-216. doi: 10.1016/j.jid.2016.07.034. Epub 2016 Aug 9.

12.

[Rapamycin opens the era of targeted molecular therapy of venous malformations].

Seront E, Limaye N, Boon LM, Vikkula M.

Med Sci (Paris). 2016 Jun-Jul;32(6-7):574-8. doi: 10.1051/medsci/20163206016. Epub 2016 Jul 12. French. No abstract available.

13.

Rebound Growth of Infantile Hemangiomas After Propranolol Therapy.

Shah SD, Baselga E, McCuaig C, Pope E, Coulie J, Boon LM, Garzon MC, Haggstrom AN, Adams D, Drolet BA, Newell BD, Powell J, García-Romero MT, Chute C, Roe E, Siegel DH, Grimes B, Frieden IJ.

Pediatrics. 2016 Apr;137(4). pii: e20151754. doi: 10.1542/peds.2015-1754. Epub 2016 Mar 7.

14.

Somatic Activating PIK3CA Mutations Cause Venous Malformation.

Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, Eklund L, Boon LM, Vikkula M.

Am J Hum Genet. 2015 Dec 3;97(6):914-21. doi: 10.1016/j.ajhg.2015.11.011.

15.

Blue bleb rubber nevus syndrome.

Ballieux F, Boon LM, Vikkula M.

Handb Clin Neurol. 2015;132:223-30. doi: 10.1016/B978-0-444-62702-5.00016-0. Review.

PMID:
26564083
16.

Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations.

Ardillon L, Lambert C, Eeckhoudt S, Boon LM, Hermans C.

Blood Coagul Fibrinolysis. 2016 Mar;27(2):216-9. doi: 10.1097/MBC.0000000000000412.

PMID:
26484645
17.

Common and specific effects of TIE2 mutations causing venous malformations.

Nätynki M, Kangas J, Miinalainen I, Sormunen R, Pietilä R, Soblet J, Boon LM, Vikkula M, Limaye N, Eklund L.

Hum Mol Genet. 2015 Nov 15;24(22):6374-89. doi: 10.1093/hmg/ddv349. Epub 2015 Aug 28.

18.

Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.

Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, Mendola A, Natynki M, Seront E, Dupont S, Hammer J, Legrand C, Brugnara C, Eklund L, Vikkula M, Bischoff J, Boon LM.

J Clin Invest. 2015 Sep;125(9):3491-504. doi: 10.1172/JCI76004. Epub 2015 Aug 10.

19.

Treatment of infantile haemangiomas: recommendations of a European expert group.

Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Ciofi Degli Atti M, El Hachem M, Oranje AP, Rubin AT, Weibel L, Léauté-Labrèze C.

Eur J Pediatr. 2015 Jul;174(7):855-65. doi: 10.1007/s00431-015-2570-0. Epub 2015 May 29. Review.

PMID:
26021855
20.

No evidence of locus heterogeneity in familial microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome.

Schlögel MJ, Mendola A, Fastré E, Vasudevan P, Devriendt K, de Ravel TJ, Van Esch H, Casteels I, Arroyo Carrera I, Cristofoli F, Fieggen K, Jones K, Lipson M, Balikova I, Singer A, Soller M, Mercedes Villanueva M, Revencu N, Boon LM, Brouillard P, Vikkula M.

Orphanet J Rare Dis. 2015 May 2;10:52. doi: 10.1186/s13023-015-0271-4.

Supplemental Content

Support Center